JUNIPER PHARMACEUTICALS INC
Healthcare · Pharmaceutical Preparations · DE · SEC filings ↗ · Compare ⊕
Financials
SEC XBRL · annual| FY17 | FY16 | FY15 | FY14 | FY13 | FY12 | |
|---|---|---|---|---|---|---|
| Revenue | $11.2M | $10.5M | $38.3M | $33.4M | $29.2M | $25.8M |
| Operating income | −$1.5M | −$1.7M | −$1.9M | $4.7M | $5.9M | $2.8M |
| Net income | −$1.4M | −$1.6M | −$1.5M | $4.7M | $6.7M | $9.9M |
| Total assets | $61.2M | $57.6M | $50.6M | $52.2M | $60.1M | $36.9M |
| Total liabilities | $19.7M | $17.3M | $13.5M | $10.8M | $12.7M | $5.0M |
| Equity | $41.5M | $39.8M | $36.5M | $37.3M | $42.1M | $31.4M |
| EPS (diluted) | $-0.13 | $-0.15 | $-0.14 | $0.39 | $0.52 | $0.26 |
| Shares out. | 10.8M | 10.8M | 10.8M | 12.2M | 87.5M | 11.1M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2017- Operating margin
- −12.9%
- Net margin
- −12.8%
- Return on equity
- −3.5%
- Return on assets
- −2.4%
- Return on capital (ROCE)
- −3.2%
- Liabilities / assets
- 32.2%
- Debt / equity
- 0.47×
- Book value / share
- $3.83
- Revenue growth (YoY)
- 7.3%
- Net income growth (YoY)
- —
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2017- Altman Z″ (distress)
- -8.57distress
- Accruals / assets
- −5.8%clean
- Piotroski F-Score
- 5/9mixed
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 2 severe● 2 warning● 4 good- Altman Z″ in the distress zone
- Filed a late-filing notice (Form NT) — missed an SEC deadline
- Operating losses (negative operating margin)
- Reported a net loss
- Revenue is growing year-over-year
- Conservative leverage (liabilities < 50% of assets)
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
Risk flags
late SEC filings- NT 10-Qmissed a reporting deadline ↗Nov 10, 2016
- NT 10-Kmissed a reporting deadline ↗Mar 18, 2008
- NT 10-Kmissed a reporting deadline ↗Mar 31, 1995
A Form NT means the company notified the SEC it would file a periodic report late — often an accounting, audit or liquidity warning sign. Also search SEC enforcement actions for this company.
Material events
SEC Form 8-K · most recent- Completed an acquisition or disposition · Delisting / listing-standard notice · Modified shareholder rights · Change in control · Director / officer change · Amended charter or bylaws · Other material eventAug 14, 2018
- Results of operationsAug 9, 2018
- Entered a material agreement · Amended charter or bylaws · Other material eventJul 3, 2018
- Results of operationsMay 10, 2018
- Entered a material agreement · Regulation FD disclosureApr 25, 2018
- Director / officer changeMar 21, 2018
- Results of operations · Item 5.08Mar 8, 2018
- Other material eventFeb 5, 2018
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 15-12BAug 31, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- EFFECTAug 30, 2018
- CT ORDERAug 30, 2018
- 4FORM 4 SUBMISSIONAug 15, 2018
- 4FORM 4 SUBMISSIONAug 15, 2018
- 4FORM 4 SUBMISSIONAug 15, 2018
- 4FORM 4 SUBMISSIONAug 15, 2018
Event-driven situations (3)
Spot an error in this record? Report it. Every correction is verified against the source filing before we change anything.